Morgan Stanley Institutional Vitality Portfolio (MSVEX)
| Fund Assets | 1.89M |
| Expense Ratio | 1.30% |
| Min. Investment | $1,000 |
| Turnover | 19.00% |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Dividend Growth | n/a |
| Payout Frequency | n/a |
| Ex-Dividend Date | n/a |
| Previous Close | 5.33 |
| YTD Return | -6.57% |
| 1-Year Return | -11.91% |
| 5-Year Return | n/a |
| 52-Week Low | 4.82 |
| 52-Week High | 6.55 |
| Beta (5Y) | n/a |
| Holdings | 37 |
| Inception Date | Dec 31, 2021 |
About MSVEX
Morgan Stanley Institutional Fund, Inc. Vitality Portfolio Class A is an actively managed mutual fund primarily focused on the U.S. healthcare sector. The portfolio invests mainly in equity securities of companies engaged in pharmaceuticals, biotechnology, healthcare equipment, and related healthcare industries. Managed by Counterpoint Global within Morgan Stanley Investment Management, the fund seeks to identify high-quality companies with sustainable competitive advantages, using a concentrated and conviction-weighted investment approach. This results in a portfolio where the top ten holdings can represent a significant portion of assets, reflecting strong beliefs in select healthcare innovators and market leaders. The fund's strategy emphasizes stock selection over broad sector allocation, aiming to differentiate from health care benchmarks such as the Russell 3000 Health Care Index. Its role in the market is to provide investors with targeted exposure to healthcare equities, seeking growth opportunities within one of the most dynamic and essential sectors of the economy. The fund is structured with a front-end load and charges an expense ratio that is above the category average, which investors should weigh alongside its active, high-conviction style.
Performance
MSVEX had a total return of -11.91% in the past year, including dividends. Since the fund's inception, the average annual return has been -4.68%.
Top 10 Holdings
55.32% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 9.02% |
| Argenx SE | n/a | 7.67% |
| UnitedHealth Group Incorporated | UNH | 6.11% |
| Vertex Pharmaceuticals Incorporated | VRTX | 5.27% |
| Exact Sciences Corporation | EXAS | 5.12% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 4.86% |
| Thermo Fisher Scientific Inc. | TMO | 4.84% |
| Intuitive Surgical, Inc. | ISRG | 4.69% |
| Ascendis Pharma A/S | ASND | 4.19% |
| Zoetis Inc. | ZTS | 3.55% |